These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38585879)

  • 1. STING-Activating Polymer-Drug Conjugates for Cancer Immunotherapy.
    Sheehy TL; Kwiatkowski AJ; Arora K; Kimmel BR; Schulman JA; Gibson-Corley K; Wilson JT
    bioRxiv; 2024 Apr; ():. PubMed ID: 38585879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STING-Activating Polymer-Drug Conjugates for Cancer Immunotherapy.
    Sheehy TL; Kwiatkowski AJ; Arora K; Kimmel BR; Schulman JA; Gibson-Corley KN; Wilson JT
    ACS Cent Sci; 2024 Sep; 10(9):1765-1781. PubMed ID: 39345818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mannosylated STING Agonist Drugamers for Dendritic Cell-Mediated Cancer Immunotherapy.
    Nguyen DC; Song K; Jokonya S; Yazdani O; Sellers DL; Wang Y; Zakaria A; Pun SH; Stayton PS
    ACS Cent Sci; 2024 Mar; 10(3):666-675. PubMed ID: 38559305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanoparticle delivery improves the pharmacokinetic properties of cyclic dinucleotide STING agonists to open a therapeutic window for intravenous administration.
    Wehbe M; Wang-Bishop L; Becker KW; Shae D; Baljon JJ; He X; Christov P; Boyd KL; Balko JM; Wilson JT
    J Control Release; 2021 Feb; 330():1118-1129. PubMed ID: 33189789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Programable Albumin-Hitchhiking Nanobodies Enhance the Delivery of STING Agonists to Potentiate Cancer Immunotherapy.
    Wilson J; Kimmel B; Arora K; Chada N; Bharti V; Kwiatkowski A; Finklestein J; Hanna A; Arner E; Sheehy T; Pastora L; Yang J; Pagendarm H; Stone P; Taylor B; Hubert L; Gibson-Corley K; May J; McLean J; Rathmell J; Richmond A; Rathmell W; Balko J; Fingleton B; Hargrove-Wiley E
    Res Sq; 2024 May; ():. PubMed ID: 38766114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma.
    Wang-Bishop L; Wehbe M; Shae D; James J; Hacker BC; Garland K; Chistov PP; Rafat M; Balko JM; Wilson JT
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32169869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Type I Photosensitizer-Polymersome Boosts Reactive Oxygen Species Generation by Forcing H-Aggregation for Amplifying STING Immunotherapy.
    Wang Z; Ma W; Yang Z; Kiesewetter DO; Wu Y; Lang L; Zhang G; Nakuchima S; Chen J; Su Y; Han S; Wu LG; Jin AJ; Huang W
    J Am Chem Soc; 2024 Oct; 146(42):28973-28984. PubMed ID: 39383053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. STING agonist and IDO inhibitor combination therapy inhibits tumor progression in murine models of colorectal cancer.
    Shi J; Liu C; Luo S; Cao T; Lin B; Zhou M; Zhang X; Wang S; Zheng T; Li X
    Cell Immunol; 2021 Aug; 366():104384. PubMed ID: 34182334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-targeted delivery of a STING agonist improvescancer immunotherapy.
    Wu YT; Fang Y; Wei Q; Shi H; Tan H; Deng Y; Zeng Z; Qiu J; Chen C; Sun L; Chen ZJ
    Proc Natl Acad Sci U S A; 2022 Dec; 119(49):e2214278119. PubMed ID: 36442099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. STING agonist diABZI enhances the cytotoxicity of T cell towards cancer cells.
    Wang L; Liang Z; Guo Y; Habimana JD; Ren Y; Amissah OB; Mukama O; Peng S; Ding X; Lv L; Li J; Chen M; Liu Z; Huang R; Zhang Y; Li Y; Li Z; Sun Y
    Cell Death Dis; 2024 Apr; 15(4):265. PubMed ID: 38615022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer.
    Lee SJ; Yang H; Kim WR; Lee YS; Lee WS; Kong SJ; Lee HJ; Kim JH; Cheon J; Kang B; Chon HJ; Kim C
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34145029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy.
    Lv M; Chen M; Zhang R; Zhang W; Wang C; Zhang Y; Wei X; Guan Y; Liu J; Feng K; Jing M; Wang X; Liu YC; Mei Q; Han W; Jiang Z
    Cell Res; 2020 Nov; 30(11):966-979. PubMed ID: 32839553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Branched glycopolymer prodrug-derived nanoassembly combined with a STING agonist activates an immuno-supportive status to boost anti-PD-L1 antibody therapy.
    Li Z; Zhang Q; Li Z; Ren L; Pan D; Gong Q; Gu Z; Cai H; Luo K
    Acta Pharm Sin B; 2024 May; 14(5):2194-2209. PubMed ID: 38799622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemical Biology Perspectives on STING Agonists as Tumor Immunotherapy.
    Xuan C; Hu R
    ChemMedChem; 2023 Dec; 18(23):e202300405. PubMed ID: 37794702
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Chellen T; Bausart M; Maus P; Vanvarenberg K; Limaye N; Préat V; Malfanti A
    Mater Today Bio; 2024 Jun; 26():101057. PubMed ID: 38660475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies involving STING pathway activation for cancer immunotherapy: Mechanism and agonists.
    Pan X; Zhang W; Guo H; Wang L; Wu H; Ding L; Yang B
    Biochem Pharmacol; 2023 Jul; 213():115596. PubMed ID: 37201875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A DNA-Modularized STING Agonist with Macrophage-Selectivity and Programmability for Enhanced Anti-Tumor Immunotherapy.
    Chen Y; Li R; Duan Q; Wu L; Li X; Luo A; Zhang Y; Zhao N; Cui K; Wu W; Liu T; Wan JB; Deng L; Li G; Hou L; Tan W; Xiao Z
    Adv Sci (Weinh); 2024 Aug; 11(32):e2400149. PubMed ID: 38898748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting STING for cancer immunotherapy: From mechanisms to translation.
    Huang R; Ning Q; Zhao J; Zhao X; Zeng L; Yi Y; Tang S
    Int Immunopharmacol; 2022 Dec; 113(Pt A):109304. PubMed ID: 36252492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade.
    Yang H; Lee WS; Kong SJ; Kim CG; Kim JH; Chang SK; Kim S; Kim G; Chon HJ; Kim C
    J Clin Invest; 2019 Jul; 129(10):4350-4364. PubMed ID: 31343989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ionizable STING-Activating Nanoadjuvants Enhance Tumor Immunogenicity and Potentiate Immunotherapy Efficacy in Solid Tumors.
    Xian S; Chen X; Ren S; Chen X; Wang H
    Cancer Res; 2024 Sep; 84(18):3044-3057. PubMed ID: 38990727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.